HAVANA, Cuba, Oct 27 (ACN) The Clinical Study Esperanza (Hope) found that Herberferon, developed by the Center for Genetic Engineering and Biotechnology (CIGB), induces negativization of SARS-CoV-2 within four days of treatment in more than 70% of the patients.
According to the institution, the study also showed that 50% of the patients tested negative to the virus two days after administration.
CIGB also reported that once the antiviral and immunomodulatory properties of Herberferon were established, it was approved for first-choice treatment of the National Action Protocol against COVID-19 designed by the Ministry of Public Health.
The inclusion of this drug in the model to treat the infectious disease allowed earlier medical discharge, namely from 14 to 9 days, and currently to 7 days.
HeberFERON was registered in 2016 for the treatment of basal cell skin cancer, especially in advanced patients and those at high risk of recurrence, using a mixture of alpha and gamma interferons in a single vial.
Cuban drug Heberferon induces early negativization of SARS-CoV-2, study confirms
Nos reservamos el derecho de no publicar los comentario que incumplan con las normas de este sitio